Pharmacologic agents for tobacco dependence treatment: 2011 update

Current Atherosclerosis Reports

Volumn 14, Issue 1, 2012, Pages 85-92

  Hays, J Taylor ^a   McFadden, David D ^a   Ebbert, Jon O ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cardiovascular disease; Pharmacotherapy; Tobacco dependence

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; NICOTINE INHALER; NICOTINE LOZENGE; NICOTINE NASAL SPRAY; NICOTINE PATCH; PLACEBO; UNCLASSIFIED DRUG; VARENICLINE;

ALCOHOLISM; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; COUGHING; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PALPITATION; HUMAN; INSOMNIA; MONOTHERAPY; MOUTH PAIN; NAUSEA; NICOTINE REPLACEMENT THERAPY; SEIZURE; SIDE EFFECT; SKIN IRRITATION; SMOKING; SMOKING CESSATION; SORE THROAT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TERATOGENICITY; TOBACCO DEPENDENCE; TREATMENT DURATION; VOMITING;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CARDIOVASCULAR DISEASES; HUMANS; NICOTINIC AGONISTS; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER;

EID: 84857631364     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0211-2     Document Type: Article

References (48)

1. Shafey O, Eriksen M, Ross H, Mackay J. The Tobacco Atlas. 3rd ed. Atlanta: American Cancer Society; 2009.
2. AH Mokdad JS Marks DF Stroup JL Gerberding 2004 Actual causes of death in the United States, 2000 JAMA 291 1238 1245 15010446 10.1001/jama.291.10.1238 (Pubitemid 38541668)
3. SA Kenfield MJ Stampfer BA Rosner GA Colditz 2008 Smoking and smoking cessation in relation to mortality in women JAMA 299 2037 2047 18460664 10.1001/jama.299.17.2037 1:CAS:528:DC%2BD1cXlslanurg%3D (Pubitemid 351656585)
4. R Doll R Peto J Boreham I Sutherland 2004 Mortality in relation to smoking: 50 years' observations on male British doctors BMJ 328 1519 1528 15213107 10.1136/bmj.38142.554479.AE (Pubitemid 38850305)
5. Fiore MC, Jaen CR, Baker TB et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guidelines. In: Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; May 2008.
6. Stead LF, Perera R, Bullen C et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008:CD000146.
7. ME Piper SS Smith TR Schlam, et al. 2009 A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies Arch Gen Psychiatry 66 1253 1262 19884613 10.1001/archgenpsychiatry.2009.142 This clinical trial demonstrated the efficacy of combination pharmacotherapy by randomizing 1504 patients to 1 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, bupropion plus nicotine lozenge, or placebo. The nicotine patch plus lozenge produced the greatest benefit relative to placebo for smoking cessation
8. SS Smith DE McCarthy SJ Japuntich, et al. 2009 Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics Arch Intern Med 169 2148 2155 20008701 10.1001/archinternmed.2009.426 This study demonstrates the effectiveness of combination pharmacotherapy in a primary care clinic setting. A total of 1346 primary care patients were randomly assigned to 1 of 5 treatments: 3 monotherapies (nicotine patch, nicotine lozenge, and bupropion hydrochloride sustained release [SR]) and 2 combination therapies (patch + lozenge and bupropion SR + lozenge). Combination pharmacotherapy significantly increased abstinence compared with monotherapies
9. MB Steinberg S Greenhaus AC Schmelzer, et al. 2009 Triple-combination pharmacotherapy for medically ill smokers: a randomized trial Ann Intern Med 150 447 454 19349630
10. RA Schnoll F Patterson EP Wileyto, et al. 2010 Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial Ann Intern Med 152 144 151 20124230 In a clinical trial randomizing 568 smokers to extended use nicotine patch (24 weeks) compared with standard 8-week therapy, extended-duration therapy was superior to standard therapy at both 24 weeks and 52 weeks
11. JT Hays RD Hurt NA Rigotti, et al. 2001 Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial Ann Intern Med 135 423 433 11560455 1:CAS:528: DC%2BD3MXntFGgtrk%3D (Pubitemid 32845867)
12. S Tonstad P Tonnesen P Hajek, et al. 2006 Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial JAMA 296 64 71 16820548 10.1001/jama.296.1.64 1:CAS:528:DC%2BD28Xms1OrtLo%3D
13. C Lerman C Jepson EP Wileyto, et al. 2010 Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy Clin Pharmacol Ther 87 553 557 20336063 10.1038/clpt.2010.3 1:CAS:528:DC%2BC3cXkvFCntLg%3D
14. LM Zapawa JR Hughes NL Benowitz, et al. 2011 Cautions and warnings on the US OTC label for nicotine replacement: what's a doctor to do? Addict Behav 36 327 332 21220188 10.1016/j.addbeh.2010.12.003
15. SS Chan DY Leung AS Abdullah, et al. 2011 A randomized controlled trial of a smoking reduction plus nicotine replacement therapy intervention for smokers not willing to quit smoking Addiction 106 1155 1163 21226883 10.1111/j.1360-0443.2011.03363.x
16. D Moore P Aveyard M Connock, et al. 2009 Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis BMJ 338 b1024 b1033 19342408 10.1136/bmj.b1024
17. S Shiffman SG Ferguson KR Strahs 2009 Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial Am J Prev Med 36 96 104 19135903 10.1016/j.amepre.2008.09.039 e101
18. JR Hughes LJ Solomon AE Livingston, et al. 2010 A randomized, controlled trial of NRT-aided gradual vs. abrupt cessation in smokers actively trying to quit Drug Alcohol Depend 111 105 113 20537810 10.1016/j.drugalcdep.2010.04.007
19. Lindson N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev. 2010:CD008033.
20. EJ Mills P Wu I Lockhart, et al. 2010 Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals Tob Induc Dis 8 8 20626883 10.1186/1617-9625-8-8 In one of the largest meta-analyses of NRT adverse effects published to date, NRT adverse effects were found to be mild overall, and there was no increase in serious adverse events such as depression or anxiety
21. RD Hurt DP Sachs ED Glover, et al. 1997 A comparison of sustained-release bupropion and placebo for smoking cessation N Engl J Med 337 1195 1202 9337378 10.1056/NEJM199710233371703 1:CAS:528:DyaK2sXntVaqsLc%3D (Pubitemid 27454451)
22. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007:CD000031.
23. RA Schnoll E Martinez KL Tatum, et al. 2010 A bupropion smoking cessation clinical trial for cancer patients Cancer Causes Control 21 811 820 20087643 10.1007/s10552-010-9507-8
24. AE Evins MA Culhane JE Alpert, et al. 2008 A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders J Clin Psychopharmacol 28 660 666 19011435 10.1097/JCP.0b013e31818ad7d6 1:CAS:528:DC%2BD1cXhtlyqu73N
25. D Catley KJ Harris KS Okuyemi, et al. 2005 The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion Nicotine Tob Res 7 859 870 16298721 10.1080/14622200500330118 1:CAS:528:DC%2BD2MXht1agtr3F (Pubitemid 43101704)
26. KE Hayford CA Patten TA Rummans, et al. 1999 Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism Br J Psychiatry 174 173 178 10211174 10.1192/bjp.174.2.173 1:STN:280:DyaK1M3islKhsg%3D%3D (Pubitemid 29089294)
27. DR Strong CW Kahler AM Leventhal, et al. 2009 Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment Nicotine Tob Res 11 1142 1153 19574407 10.1093/ntr/ntp111 1:CAS:528:DC%2BD1MXhtFOht77O
28. BF Grant DS Hasin SP Chou, et al. 2004 Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions Arch Gen Psychiatry 61 1107 1115 15520358 10.1001/archpsyc.61.11.1107 (Pubitemid 39463411)
29. JT Hays DR Schroeder KP Offord, et al. 1999 Response to nicotine dependence treatment in smokers with current and past alcohol problems Ann Behav Med 21 244 250 10626032 10.1007/BF02884841 1:STN:280:DC%2BD3c%2FptFCktQ%3D%3D
30. RD Hurt LC Dale KP Offord, et al. 1995 Nicotine patch therapy for smoking cessation in recovering alcoholics Addiction 90 1541 1546 8528039 10.1111/j.1360-0443.1995.tb02816.x 1:STN:280:DyaK287gt1ersA%3D%3D
31. JT Hays RD Hurt PA Decker, et al. 2009 A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics Nicotine Tob Res 11 859 867 19483180 10.1093/ntr/ntp077 1:CAS:528:DC%2BD1MXotVGrsbc%3D
32. A Boshier LV Wilton SA Shakir 2003 Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000 Eur J Clin Pharmacol 59 767 773 14615857 10.1007/s00228-003- 0693-0 1:CAS:528:DC%2BD3sXpslOit70%3D (Pubitemid 38041302)
33. R Hubbard S Lewis J West, et al. 2005 Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network Thorax 60 848 850 16055620 10.1136/thx.2005.041798 1:STN:280: DC%2BD2MrhvF2hsg%3D%3D (Pubitemid 41475213)
34. MN Beyens C Guy G Mounier, et al. 2008 Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004 Drug Saf 31 1017 1026 18840021 10.2165/00002018- 200831110-00006 1:CAS:528:DC%2BD1cXhsFWgsrfP
35. ME Thase BR Haight MC Johnson, et al. 2008 A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension J Clin Psychopharmacol 28 302 307 18480687 10.1097/JCP.0b013e318172424e 1:CAS:528:DC%2BD1cXmvFehurY%3D
36. S Alwan J Reefhuis LD Botto, et al. 2010 Maternal use of bupropion and risk for congenital heart defects Am J Obstet Gynecol 203 52 e51 e56
37. D Gonzales SI Rennard M Nides, et al. 2006 Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial JAMA 296 47 55 16820546 10.1001/jama.296.1.47 1:CAS:528:DC%2BD28Xms1OrtLw%3D
38. DE Jorenby JT Hays NA Rigotti, et al. 2006 Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial JAMA 296 56 63 16820547 10.1001/jama.296.1.56 1:CAS:528:DC%2BD28Xms1OrtL0%3D
39. • Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2011:CD006103. This large systematic review observed that varenicline increased the chances of successful long-term smoking cessation between two- and threefold compared with pharmacologically unassisted quit attempts. Varenicline was also observed to be superior to bupropion. The main adverse effect of varenicline is nausea but mostly at mild to moderate levels and tending to subside over time.
40. NA Rigotti AL Pipe NL Benowitz, et al. 2010 Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial Circulation 121 221 229 20048210 10.1161/CIRCULATIONAHA.109. 869008 1:CAS:528:DC%2BC3cXktVCnsg%3D%3D
41. DP Tashkin S Rennard JT Hays, et al. 2011 Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial Chest 139 591 599 20864613 10.1378/chest.10-0865
42. U.S. Food and Drug Administration. FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. Available at http://www.fda.gov/Drugs/ DrugSafety/ucm259161.htm. Accessed June 2011.
43. • Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011, July 5 [Epub ahead of print]. This meta-analysis of serious cardiovascular events associated with varenicline shows a small but statistically significant increase in cardiovascular events with varenicline compared with placebo.
44. Hays JT. Varenicline for smoking cessation: is it a heartbreaker? CMAJ. 2011, July 5 [Epub ahead of print].
45. U.S. Food and Drug Administration 2009 The smoking cessation aids varenicline (marketed as chantix) and bupropion (marketed as zyban and generics): suicidal ideation and behavior FDA Safety Newsletter 2 1 4
46. D Gunnell D Irvine L Wise, et al. 2009 Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database BMJ 339 b3805 19797344 10.1136/bmj.b3805 1:STN:280: DC%2BD1Mnmt1KjsQ%3D%3D In a retrospective analysis of 10,973 tobacco-dependent patients who used varenicline in a general practice setting, varenicline treatment was associated with similar rates of depression, self-harm, and suicidal thoughts as NRT. This further supports the growing body of medical literature questioning the causal relationship of varenicline to worsening depression and suicidal ideation
47. S Tonstad S Davies M Flammer, et al. 2010 Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis Drug Saf 33 289 301 20297861 10.2165/11319180-000000000-00000 1:CAS:528:DC%2BC3cXls12murg%3D
48. JA Stapleton L Watson LI Spirling, et al. 2008 Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness Addiction 103 146 154 18028247 10.1111/j.1360-0443.2007.02083.x (Pubitemid 350233424)